Select Page
Advanced NSCLC: EC Approval of Lumykras Treatment

Advanced NSCLC: EC Approval of Lumykras Treatment

The European Commission (EC) has granted a conditional marketing authorization for Amgen’s LUMYKRAS (sotorasib) to treat advanced non-small cell lung cancer (NSCLC) with the KRAS G12C mutation in adults. NSCLC is the leading lung cancer diagnosis globally and includes...